Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : announces the publication of New Contents related to its Corporate Strategic Plan 2021 and an Update to its About Section

09/30/2021 | 05:23am EST

This is to notify you that Astellas has published new contents related to its Corporate Strategic Plan 2021 (CSP2021) and updated its About section.

1.New Contents Related to CSP 2021

2 contents related to CSP 2021 have been published as below.


(1) Stories: Corporate Strategic Plan 2021-dedicated to realization

In this Story article, President and CEO: Kenji Yasukawa, Ph.D., explains how CSP 2021 came about and his dedication to it, which is charged with realizing Astellas' VISION, On the forefront of healthcare change to turn innovative science into VALUE for patients. This Story also introduces Astellas' strength to successfully execute CSP2021. You can read about Astellas' commitment of creating and delivering VALUE to patients, their families who support them, caregivers, medical facilities, and ultimately the whole society.

Please click here to read the Story: Corporate Strategic Plan 2021-dedicated to realization.


(2) CSP 2021 Introduction page

In this new page, we introduce CSP2021 that we announced on May 26th, 2021 to all stakeholders.
This page shows our path of promoting business to achieve 3 types of new goal, namely, the Strategic Goals, Organizational Health Goals, and Performance Goals, through CSP 2021 which further develops upon our fundamental strategy for the next 5 years.

Please click here for the Introduction page of CSP 2021.


2. About Section Renewal

We also updated the About section in the Corporate Website. The overall structure was fixed, and a portion of the content and the design were updated so that all stakeholders can easily access the required information and readily understand it.

Please click here to About section.

Astellas, through its corporate website, will continue to work towards the timely, proper, and reliable disclosure of information to all stakeholders in conjunction with delivering content that presents Astellas' strategy and business activities in a comprehensive manner.

Disclaimer

Astellas Pharma Inc. published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 09:21:04 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
12/07Astellas Applied for Selection of 'Prime Market' segment of the Tokyo Stock Exchange
AQ
12/06ASTELLAS PHARMA : New Research Organization Structure
PU
12/06ASTELLAS PHARMA : Presentation Material for R&D Meeting
PU
12/06ASTELLAS PHARMA : Corporate Governance Report
PU
12/06ASTELLAS PHARMA : Applied for Selection of “Prime Market”segment of the Tokyo ..
PU
12/06ASTELLAS PHARMA : Applied for Selection of “Prime Market” segment of the Tokyo..
PU
12/05ASTELLAS PHARMA : Corporate Covernance Report
PU
12/02Astellas to Present Research on FLT3 Mutation, Positive Acute Myeloid Leukemia from Dia..
AQ
12/02Japanese shares end lower on Omicron worries, Fed's hawkish tilt
RE
12/01Japanese shares fall on Omicron, Fed worries
RE
More news
Financials
Sales 2022 1 327 B 11 691 M 11 691 M
Net income 2022 183 B 1 612 M 1 612 M
Net cash 2022 380 B 3 347 M 3 347 M
P/E ratio 2022 17,9x
Yield 2022 2,81%
Capitalization 3 300 B 29 053 M 29 066 M
EV / Sales 2022 2,20x
EV / Sales 2023 1,93x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 781,00 JPY
Average target price 2 458,33 JPY
Spread / Average Target 38,0%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.11.73%29 053
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215